SEC Form 6-K Summary
Registrant: NLS Pharmaceutics Ltd. The supplied metadata identifies Newcelx Ltd., which does not match the registrant named in the filing.
Business Context and Reporting Period
This Form 6-K was filed on October 6, 2022, for the month of October 2022 (Report No. 2). It reports an upcoming shareholder meeting and a Nasdaq delisting matter. The filing is incorporated by reference into the registrant’s Form F-3 registration statement.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial performance figures.
Material Changes and Corporate Events
- An Extraordinary Shareholders’ Meeting is scheduled for October 27, 2022.
- Shareholders of record as of the close of business on October 24, 2022, are entitled to vote at the meeting and any postponement or adjournment.
- On October 5, 2022, the company announced receipt of a Nasdaq Staff delisting determination and stated that it intends to request a hearing.
Guidance, Risks, Contingencies, and Unusual Items
The Nasdaq delisting determination is a material regulatory and listing-status risk. The company’s planned hearing request may affect the timing and outcome of any delisting action, but the filing does not provide the underlying Nasdaq deficiency, hearing date, or expected resolution.
The filing contains an apparent inconsistency: the main text refers to an Extraordinary Shareholders’ Meeting, while the exhibit index describes a Notice of Meeting and Proxy Card for an Ordinary Shareholders’ Meeting.
Investor Verification Items
- Confirm the correct registrant identity, because the supplied company metadata differs from the filing.
- Review the full proxy materials for the October 27, 2022 meeting and the matters submitted for shareholder approval.
- Review Exhibit 99.2 for the Nasdaq delisting grounds, hearing procedures, deadlines, and potential consequences.
- Verify whether the meeting is extraordinary or ordinary and confirm the October 24, 2022 record date.
- Assess the company’s current listing status and any subsequent Nasdaq or SEC filings.